Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 1/2021

Open Access 01-12-2021 | Correction

Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent

Authors: Zoltan Szucs, James Joseph, Tim J. Larkin, Bangwen Xie, Sarah E. Bohndiek, Kevin M. Brindle, André A. Neves

Published in: Breast Cancer Research | Issue 1/2021

Login to get access

Excerpt

Correction to: Breast Cancer Res (2021) 23:25 …
Literature
1.
Metadata
Title
Correction to: Multi-modal imaging of high-risk ductal carcinoma in situ of the breast using C2Am: a targeted cell death imaging agent
Authors
Zoltan Szucs
James Joseph
Tim J. Larkin
Bangwen Xie
Sarah E. Bohndiek
Kevin M. Brindle
André A. Neves
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2021
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/s13058-021-01414-x

Other articles of this Issue 1/2021

Breast Cancer Research 1/2021 Go to the issue

Research article

Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

Research article

Body fatness and breast cancer risk in relation to phosphorylated mTOR expression in a sample of predominately Black women

Research article

Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy

Research article

Urinary phthalate exposures and risk of breast cancer: the Multiethnic Cohort study

Research article

TAZ maintains telomere length in TNBC cells by mediating Rad51C expression

Research article

The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits